Healthcare Nov 26, 2021 02:35 PM (GMT+8) · EqualOcean
Yiouda health news on November 26. Recently, the ch-vad implantable left ventricular assist system independently developed by Tongxin medical has been officially approved by the State Drug Administration (nmpa) (Registration Certificate No.: gxzz 20213120987). This is the first domestic artificial heart with complete independent intellectual property rights approved by nmpa in China and the first full magnetic levitation artificial heart approved by nmpa in the world. It marks the commercialization of ventricular assist device products of the global new generation technology route (full magnetic levitation technology route) in China and will open a new era of heart failure treatment in China. Ch-vad implantable left ventricular assist system is composed of implanted parts in vivo, carried parts in vitro, peripheral parts and special surgical tools. It is an electromechanical device used to partially replace the heart to complete the blood pumping function and maintain human blood circulation. Its core component is a blood pump, which leads the blood out of the heart, increases the pressure and then sends it to the aorta, so as to achieve the function of unloading the load of the natural heart, make the natural heart rest, and supplement the problem of insufficient blood pumping capacity of the natural heart. It is mainly used to treat patients with end-stage severe heart failure, To provide hemodynamic support for patients with advanced refractory left ventricular heart failure.